

Idiopathic Pulmonary Fibrosis (IPF)

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03115619 ML39259

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT03115619 ML39259
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years

Healthy Volunteers
No
